1. Transformation of the tobacco product market in Japan, 2011-2023.
- Author
-
Cummings KM, Roberson A, Levy DT, Meza R, Warner KE, Fong GT, Xu SS, Gravely S, Dhungel B, Borland R, O'Connor RJ, Goniewicz ML, and Sweanor DT
- Abstract
Objective: This study updates a previous paper that examined trends in the sale of cigarettes and heated tobacco products (HTPs) in Japan between 2011 and part way through 2019. The current study includes complete unit sales data through 2023., Methods: Data on cigarette and HTP sales were obtained from public sources available from the websites and stockholder reports for the Tobacco Institute of Japan, Philip Morris International and Japan Tobacco. We used joinpoint regression using the parametric method to test for trends in both per capita and total sales for the three outcome variables assessed between 2011 and 2023: (1) cigarette sales, (2) HTP sales and (3) combined cigarette and HTP sales. Joinpoint regression identifies changes in trends and estimates the annual per cent change (APC) for each trend segment., Results: Between 2011 and 2023, per capita and total cigarette sales declined by 52.6% and 52.7%, respectively. From 2011 to 2015, per capita cigarette sales in Japan decreased -1.5% APC; from 2015 to 2018, the decline accelerated to -10.5% APC and continued to fall -7.3% APC between 2018 and 2023. Between 2016 and 2018, per capita HTP sales increased by 149.0% APC, and since 2018, they have increased by 8.1% APC., Conclusion: While many factors may account for the decreased sale of cigarettes in Japan over the past 12 years, the increased sale of HTPs appears to be a factor., Competing Interests: Competing interests: KMC has been a paid expert witness in litigation against the cigarette industry. MLG received a research grant from Pfizer and served as a member of the scientific advisory board of Johnson & Johnson. GTF has served as an expert witness and consultant for governments defending their country’s tobacco control policies and regulations in litigation, and was and unpaid member of he Health Canada Vaping Products Scientific Advisory Group 2017-2020. All others have no conflicts of interest to declare., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF